Cytiva Bioprocess v. JSR Corporation: Federal Circuit splits verdict on protein A chromatography patents
Cytiva Bioprocess R&D AB and JSR Corporation clashed at the Federal Circuit over three patents covering domain C-based protein A chromatography ligands used in biopharmaceutical antibody purification. After 527 days, the court issued a mixed judgment — affirming some PTAB findings and reversing others — leaving the patent landscape in this critical bioprocessing niche partially reshaped.
Federal Circuit delivers split ruling on Cytiva’s antibody purification IP
Cytiva Bioprocess R&D AB, a GE Healthcare spin-off and leading bioprocessing IP holder, filed appeal case 23-2074 on 26 June 2023 before the Court of Appeals for the Federal Circuit, challenging PTAB decisions concerning three US patents — US10875007B2, US10343142B2, and US10213765B2 — covering chromatography ligands derived from domain C of Staphylococcus aureus protein A, a cornerstone technology in industrial-scale antibody isolation and biopharmaceutical manufacturing.
The Federal Circuit closed the case on 4 December 2024 with a verdict of ‘Affirmed-in-Part and Reversed-in-Part,’ characterised as a mixed judgment. This outcome means the appellate court found no reversible error in certain PTAB patentability determinations — preserving some invalidity or validity findings — while simultaneously identifying legal or factual error in others, effectively reinstating or nullifying discrete claim sets depending on which rulings were reversed.
At 527 days, the appeal duration is consistent with the complexity of multi-patent biotech IPR appeals at the Federal Circuit, where claim construction disputes and obviousness analyses over protein engineering can be technically dense. The mixed outcome suggests the merits were genuinely contested across the three patents rather than a clear sweep for either party. What specific claims survive, and whether either party will seek en banc review or certiorari, remains unclear from the public record available at this stage.
Filing to Mixed Judgment in 527 days
527 days from filing to decision — above the Federal Circuit median for multi-patent IPR appeals
Federal Circuit split: what affirmed-in-part and reversed-in-part means for both parties
What ‘affirmed-in-part, reversed-in-part’ means at the Federal Circuit
A mixed Federal Circuit judgment means the court reviewed each PTAB patentability determination independently and reached different conclusions across them. Where affirmed, the lower tribunal’s reasoning contained no reversible error — those findings stand as law. Where reversed, the Federal Circuit identified a legal or factual error requiring a different outcome, which may reinstate claims previously cancelled or invalidate claims previously upheld. No single party walks away with a complete win.
Partial merits rulingCytiva recovers on some claims — enforceability picture remains mixed
For Cytiva, the reversals represent a meaningful recovery: claims that PTAB had cancelled may be reinstated, restoring enforcement leverage in the protein A chromatography ligand space. However, the affirmed portions confirm that some claims did not survive patentability scrutiny, narrowing the overall IP perimeter. Cytiva’s ability to assert the surviving estate against competitors — including JSR — will depend on which specific claims fall on which side of the split.
Partial claim survivalJSR secures some cancellations but loses ground on reversed claims
JSR Corporation and JSR Life Sciences secured permanent cancellation of any claims covered by the affirmed invalidity findings — a meaningful freedom-to-operate benefit in the antibody purification resin market. However, the reversed portions likely reinstate Cytiva patent claims that JSR had previously succeeded in challenging at the PTAB. JSR’s exposure to infringement risk from reinstated claims will require a fresh assessment of its product lines against the surviving claim language.
Partial invalidity securedBiopharmaceutical purification IP landscape remains contested post-ruling
Protein A chromatography resins are a multi-billion dollar input for monoclonal antibody manufacturing, making this IP estate commercially critical. The mixed Federal Circuit ruling leaves the sector in a state of partial clarity: some competitive space opens where claims were affirmed invalid, while other product and process areas remain under Cytiva’s patent umbrella where claims were reversed in its favour. Biosimilar developers and resin manufacturers should map surviving claim scope before making capacity or supply-chain commitments.
Sector IP risk remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cytiva Bioprocess R & D, AB | Individual | Bioprocessing IP holder — holder of US10875007B2, US10343142B2, US10213765B2Search in Eureka ↗ |
| Defendant | JSR Corporation | Company | JSR Corporation and JSR Life Sciences LLC — life sciences materials and chromatography resin developersSearch in Eureka ↗ |
| Co-Defendant | Jsr Life Sciences, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Leon Hoffman | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Plaintiff counsel | David M. Krinsky | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP | Law Firm | Representing Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings, LLP | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ‘Affirmed-in-Part and Reversed-in-Part’ disposition across three protein A chromatography patents reflects a claim-differentiated appellate analysis. At the Federal Circuit, PTAB patentability determinations on questions of law — including claim construction — are reviewed de novo, while factual findings underlying obviousness are reviewed for substantial evidence. A partial reversal typically signals the court identified at least one legal error or unsupported factual inference at the PTAB level on discrete claims, while finding the remaining determinations adequately supported. The mixed judgment means neither party achieved a clean outcome, and the practical enforceability of each patent now turns on the specific claims covered by each portion of the ruling.
US10875007B2, US10343142B2 & US10213765B2 — Protein A chromatography ligands for antibody isolation
The three patents at issue — US10875007B2, US10343142B2, and US10213765B2 — cover chromatography ligands built around domain C of Staphylococcus aureus protein A, engineered for selective binding and elution of antibodies in industrial bioprocessing columns. Protein A affinity chromatography is the dominant platform technology for monoclonal antibody purification, and domain C-based ligands represent a structurally defined subset with specific binding geometry and alkaline stability characteristics relevant to manufacturing process design.
These patents occupy a commercially critical position in biopharmaceutical supply chains: virtually every monoclonal antibody approved globally passes through a protein A affinity step during manufacturing. Cytiva (formerly GE Healthcare Life Sciences) holds a dominant market position in protein A resin supply, and this patent estate underpins its ability to exclude competitors — including JSR, a significant Japanese life sciences materials group — from the engineered ligand segment. The Federal Circuit’s partial reversal suggests at least some of this competitive moat has been judicially reinforced.
Should you run an FTO against US10875007B2, US10343142B2, and US10213765B2?
Any organisation developing, manufacturing, or sourcing protein A chromatography resins for antibody purification — including biosimilar manufacturers, contract development and manufacturing organisations (CDMOs), and resin suppliers — should treat this Federal Circuit ruling as a trigger for a fresh FTO analysis. The mixed outcome means the surviving claim scope is non-trivial and the specific claims reinstated by the reversal portions may directly cover engineered domain C ligand structures in commercial use.
PatSnap Eureka’s FTO Search Agent can map the claim language of all three patents against your specific ligand structure, resin product, or manufacturing workflow, cross-referenced against the Federal Circuit’s disposition to identify which claims are active enforcement risks versus those confirmed invalid. Eureka’s citation landscape analysis also surfaces related Cytiva prosecution history and continuation filings that may create additional coverage beyond these three patents.
Run a freedom-to-operate analysis on US10875007B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in protein A and bioprocessing chromatography IP
Cases involving Federal Circuit review of PTAB patentability decisions on protein A and bioprocessing chromatography ligand patents — comparable technology domain and appellate posture.
What this case signals for the bioprocessing chromatography IP landscape
The Federal Circuit’s split ruling reshapes enforceability across protein A resin IP — with consequences for antibody manufacturers, resin suppliers, and biosimilar developers.
Mixed Federal Circuit verdicts demand claim-level mapping, not portfolio-level assumptions
A split affirmance/reversal means the enforceability of Cytiva’s protein A estate now varies claim by claim. Companies operating in the antibody purification space cannot assume blanket freedom or blanket risk — each claim family requires independent FTO analysis against the precise Federal Circuit disposition to understand actual exposure.
JSR’s IPR strategy produced partial but not complete invalidity — a common biopharmaceutical outcome
The mixed result is consistent with Federal Circuit treatment of protein engineering patents where obviousness arguments succeed against some claims but fail against structurally differentiated variants. For IPR petitioners in life sciences, this case reinforces that claim-by-claim challenge strategies rarely yield total invalidation of well-drafted bioprocessing portfolios.
AB v JSR — key questions answered
The Federal Circuit issued an ‘Affirmed-in-Part and Reversed-in-Part’ ruling on 4 December 2024, upholding some PTAB patentability determinations while reversing others across three Cytiva protein A chromatography ligand patents (US10875007B2, US10343142B2, US10213765B2). The mixed judgment means neither party achieved a complete outcome.
Three US patents were at issue: US10875007B2, US10343142B2, and US10213765B2. All three cover chromatography ligands based on domain C of Staphylococcus aureus protein A, used in affinity chromatography for industrial-scale monoclonal antibody isolation and purification.
It means the Federal Circuit reviewed each PTAB patentability determination separately and reached different conclusions. Affirmed portions stand — those PTAB findings contain no reversible error. Reversed portions indicate identified legal or factual error; claims cancelled by PTAB on those grounds may be reinstated, while claims upheld may be invalidated, depending on direction.
Protein A affinity chromatography is the dominant purification method for monoclonal antibodies, a market worth tens of billions of dollars annually. Patents covering engineered protein A ligands — particularly domain C variants with improved stability and binding properties — directly control which resin suppliers can compete and what manufacturing processes biosimilar and innovator biologics companies can use commercially.
Yes. The mixed ruling means that some previously cancelled claims may be reinstated, altering the FTO landscape for companies using protein A chromatography in antibody manufacturing. Organisations that relied on PTAB cancellations for FTO clearance should obtain updated opinions covering the specific claims affected by the reversal portions of the Federal Circuit’s decision.
PatSnap Eureka searches patents and litigation data to answer instantly.